Please enable JavaScript to continue using this application.

Compare $CRL vs $RGEN | Chartloom

Compare

$CRL vs $RGEN

Charles River Laboratories International Inc · Repligen Corp

CRL

Charles River Laboratories International Inc

RGEN

Repligen Corp

Compare $CRL vs $RGEN

Comparing Charles River Laboratories International Inc and Repligen Corp

CRLCharles River Laboratories International Inc

RGENRepligen Corp

CRLCharles River Laboratories International Inc

Market cap

$14.54B

P/E (TTM)

—

Forward P/E (NTM)

24.21x

Forward P/S (NTM)

3.68x

Rev growth (TTM)

-0.7%

YTD performance

49.1%

52W performance

74.0%

FCF yield

2.5%

RGENRepligen Corp

Market cap

$9.81B

P/E (TTM)

237.08x

Forward P/E (NTM)

75.08x

Forward P/S (NTM)

10.82x

Rev growth (TTM)

16.5%

YTD performance

5.8%

52W performance

15.3%

FCF yield

1.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CRL

RGEN

Detailed metrics comparison

CRL

Charles River Laboratories International Inc

RGEN

Repligen Corp

Market Cap

CRL$14.54B

RGEN$9.81B

Enterprise Value

CRL$16.97B

RGEN$9.76B

Price

CRL$301.79

RGEN$173.88

P/E Ratio

CRLN/A

RGEN237.08x

P/S Ratio

CRL3.64x

RGEN12.50x

EV/Sales

CRL4.24x

RGEN12.43x

EV/EBITDA

CRL19.41x

RGEN64.73x

P/B Ratio

CRL4.88x

RGEN4.86x

P/FCF Ratio

CRL39.23x

RGEN89.09x

EV/FCF

CRL45.79x

RGEN88.59x

PEG Ratio

CRLN/A

RGEN11.27x

Forward P/E (NTM)

CRL24.21x

RGEN75.08x

Forward P/S (NTM)

CRL3.68x

RGEN10.82x

Revenue (TTM)

CRL$4.00B

RGEN$785M

Revenue Growth (YoY)

CRL-0.7%

RGEN16.5%

Forward Rev Growth

CRL2.3%

RGEN17.6%

Gross Margin (TTM)

CRL34.6%

RGEN53.8%

Operating Margin (TTM)

CRL2.3%

RGEN6.5%

EBITDA Margin (TTM)

CRL21.6%

RGEN18.8%

Net Margin (TTM)

CRL-6.0%

RGEN5.3%

FCF Margin (TTM)

CRL9.3%

RGEN14.0%

Net Income (TTM)

CRL$-238M

RGEN$42M

FCF (TTM)

CRL$371M

RGEN$110M

EPS (TTM)

CRL-$4.97

RGEN$0.73

ROE (TTM)

CRL-772.0%

RGEN2.0%

ROA (TTM)

CRL-319.0%

RGEN1.4%

ROIC (TTM)

CRL-434.0%

RGEN1.6%

Cash

CRL$192M

RGEN$607M

Debt

CRL$2.63B

RGEN$551M

Net Cash/Debt

CRL$-2.43B

RGEN$56M

Current Ratio (TTM)

CRL1.35x

RGEN9.05x

Quick Ratio (TTM)

CRL0.83x

RGEN7.30x

Debt/Equity (TTM)

CRL0.93x

RGEN0.26x

Debt/Assets (TTM)

CRL0.0%

RGEN0.0%

Interest Coverage (TTM)

CRLN/A

RGENN/A

Net Debt/EBITDA (TTM)

CRL0.00x

RGEN0.00x

Beta

CRL1.38

RGEN1.13

52W Performance

CRL74.0%

RGEN15.3%

YTD Performance

CRL49.1%

RGEN5.8%

% from 52W High

CRL-9.5%

RGEN-12.6%

% from 52W Low

CRL106.4%

RGEN72.2%

Asset Turnover (TTM)

CRL0.53x

RGEN0.27x

FCF Yield (TTM)

CRL2.5%

RGEN1.1%

Earnings Yield (TTM)

CRL-1.6%

RGEN0.4%

Dividend Yield (TTM)

CRLN/A

RGENN/A

Rule of 40

CRL8.5

RGEN30.5

EV/GP/RG

CRL5.20

RGEN1.46

Ticker research

View CRL research View RGEN research

Metric	CRL Charles River Laboratories International Inc	RGEN Repligen Corp
Market & Valuation
Market Cap	$14.54B	$9.81B
Enterprise Value	$16.97B	$9.76B
Price	$301.79	$173.88
P/E Ratio	N/A	237.08x
P/S Ratio	3.64x	12.50x
EV/Sales	4.24x	12.43x
EV/EBITDA	19.41x	64.73x
P/B Ratio	4.88x	4.86x
P/FCF Ratio	39.23x	89.09x
EV/FCF	45.79x	88.59x
PEG Ratio	N/A	11.27x
Forward P/E (NTM)	24.21x	75.08x
Forward P/S (NTM)	3.68x	10.82x
Revenue & Growth
Revenue (TTM)	$4.00B	$785M
Revenue Growth (YoY)	-0.7%	16.5%
Forward Rev Growth	2.3%	17.6%
Profitability
Gross Margin (TTM)	34.6%	53.8%
Operating Margin (TTM)	2.3%	6.5%
EBITDA Margin (TTM)	21.6%	18.8%
Net Margin (TTM)	-6.0%	5.3%
FCF Margin (TTM)	9.3%	14.0%
Net Income (TTM)	$-238M	$42M
FCF (TTM)	$371M	$110M
EPS (TTM)	-$4.97	$0.73
ROE (TTM)	-772.0%	2.0%
ROA (TTM)	-319.0%	1.4%
ROIC (TTM)	-434.0%	1.6%
Financial Health
Cash	$192M	$607M
Debt	$2.63B	$551M
Net Cash/Debt	$-2.43B	$56M
Current Ratio (TTM)	1.35x	9.05x
Quick Ratio (TTM)	0.83x	7.30x
Debt/Equity (TTM)	0.93x	0.26x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.38	1.13
52W Performance	74.0%	15.3%
YTD Performance	49.1%	5.8%
% from 52W High	-9.5%	-12.6%
% from 52W Low	106.4%	72.2%
Efficiency & Yields
Asset Turnover (TTM)	0.53x	0.27x
FCF Yield (TTM)	2.5%	1.1%
Earnings Yield (TTM)	-1.6%	0.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.5	30.5
EV/GP/RG	5.20	1.46
Ticker research	View CRL research	View RGEN research

Valuation

P/E Ratio

RGEN

237.08x

P/S Ratio

CRL

3.64x

RGEN

12.50x

EV/FCF

CRL

45.79x

RGEN

88.59x

Growth & revenue

Revenue Growth TTM

RGEN

16.5%

CRL

-0.7%

Forward Revenue Growth

RGEN

17.6%

CRL

2.3%

Profitability & performance

Gross Margin

RGEN

53.8%

CRL

34.6%

ROE

RGEN

2.0%

CRL

-772.0%

FCF Yield %

CRL

2.5%

RGEN

1.1%

52-Week Performance

CRL

74.0%

RGEN

15.3%

Detailed metrics comparison

CRL

Charles River Laboratories International Inc

RGEN

Repligen Corp

Market Cap

CRL$14.54B

RGEN$9.81B

Enterprise Value

CRL$16.97B

RGEN$9.76B

Price

CRL$301.79

RGEN$173.88

P/E Ratio

CRLN/A

RGEN237.08x

P/S Ratio

CRL3.64x

RGEN12.50x

EV/Sales

CRL4.24x

RGEN12.43x

EV/EBITDA

CRL19.41x

RGEN64.73x

P/B Ratio

CRL4.88x

RGEN4.86x

P/FCF Ratio

CRL39.23x

RGEN89.09x

EV/FCF

CRL45.79x

RGEN88.59x

PEG Ratio

CRLN/A

RGEN11.27x

Forward P/E (NTM)

CRL24.21x

RGEN75.08x

Forward P/S (NTM)

CRL3.68x

RGEN10.82x

Revenue (TTM)

CRL$4.00B

RGEN$785M

Revenue Growth (YoY)

CRL-0.7%

RGEN16.5%

Forward Rev Growth

CRL2.3%

RGEN17.6%

Gross Margin (TTM)

CRL34.6%

RGEN53.8%

Operating Margin (TTM)

CRL2.3%

RGEN6.5%

EBITDA Margin (TTM)

CRL21.6%

RGEN18.8%

Net Margin (TTM)

CRL-6.0%

RGEN5.3%

FCF Margin (TTM)

CRL9.3%

RGEN14.0%

Net Income (TTM)

CRL$-238M

RGEN$42M

FCF (TTM)

CRL$371M

RGEN$110M

EPS (TTM)

CRL-$4.97

RGEN$0.73

ROE (TTM)

CRL-772.0%

RGEN2.0%

ROA (TTM)

CRL-319.0%

RGEN1.4%

ROIC (TTM)

CRL-434.0%

RGEN1.6%

Cash

CRL$192M

RGEN$607M

Debt

CRL$2.63B

RGEN$551M

Net Cash/Debt

CRL$-2.43B

RGEN$56M

Current Ratio (TTM)

CRL1.35x

RGEN9.05x

Quick Ratio (TTM)

CRL0.83x

RGEN7.30x

Debt/Equity (TTM)

CRL0.93x

RGEN0.26x

Debt/Assets (TTM)

CRL0.0%

RGEN0.0%

Interest Coverage (TTM)

CRLN/A

RGENN/A

Net Debt/EBITDA (TTM)

CRL0.00x

RGEN0.00x

Beta

CRL1.38

RGEN1.13

52W Performance

CRL74.0%

RGEN15.3%

YTD Performance

CRL49.1%

RGEN5.8%

% from 52W High

CRL-9.5%

RGEN-12.6%

% from 52W Low

CRL106.4%

RGEN72.2%

Asset Turnover (TTM)

CRL0.53x

RGEN0.27x

FCF Yield (TTM)

CRL2.5%

RGEN1.1%

Earnings Yield (TTM)

CRL-1.6%

RGEN0.4%

Dividend Yield (TTM)

CRLN/A

RGENN/A

Rule of 40

CRL8.5

RGEN30.5

EV/GP/RG

CRL5.20

RGEN1.46

Ticker research

View CRL research View RGEN research

Metric	CRL Charles River Laboratories International Inc	RGEN Repligen Corp
Market & Valuation
Market Cap	$14.54B	$9.81B
Enterprise Value	$16.97B	$9.76B
Price	$301.79	$173.88
P/E Ratio	N/A	237.08x
P/S Ratio	3.64x	12.50x
EV/Sales	4.24x	12.43x
EV/EBITDA	19.41x	64.73x
P/B Ratio	4.88x	4.86x
P/FCF Ratio	39.23x	89.09x
EV/FCF	45.79x	88.59x
PEG Ratio	N/A	11.27x
Forward P/E (NTM)	24.21x	75.08x
Forward P/S (NTM)	3.68x	10.82x
Revenue & Growth
Revenue (TTM)	$4.00B	$785M
Revenue Growth (YoY)	-0.7%	16.5%
Forward Rev Growth	2.3%	17.6%
Profitability
Gross Margin (TTM)	34.6%	53.8%
Operating Margin (TTM)	2.3%	6.5%
EBITDA Margin (TTM)	21.6%	18.8%
Net Margin (TTM)	-6.0%	5.3%
FCF Margin (TTM)	9.3%	14.0%
Net Income (TTM)	$-238M	$42M
FCF (TTM)	$371M	$110M
EPS (TTM)	-$4.97	$0.73
ROE (TTM)	-772.0%	2.0%
ROA (TTM)	-319.0%	1.4%
ROIC (TTM)	-434.0%	1.6%
Financial Health
Cash	$192M	$607M
Debt	$2.63B	$551M
Net Cash/Debt	$-2.43B	$56M
Current Ratio (TTM)	1.35x	9.05x
Quick Ratio (TTM)	0.83x	7.30x
Debt/Equity (TTM)	0.93x	0.26x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.38	1.13
52W Performance	74.0%	15.3%
YTD Performance	49.1%	5.8%
% from 52W High	-9.5%	-12.6%
% from 52W Low	106.4%	72.2%
Efficiency & Yields
Asset Turnover (TTM)	0.53x	0.27x
FCF Yield (TTM)	2.5%	1.1%
Earnings Yield (TTM)	-1.6%	0.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.5	30.5
EV/GP/RG	5.20	1.46
Ticker research	View CRL research	View RGEN research